• LAST PRICE
    7.8600
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.1274%)
  • Bid / Lots
    7.8500/ 1
  • Ask / Lots
    7.8700/ 1
  • Open / Previous Close
    7.7100 / 7.8500
  • Day Range
    Low 7.7100
    High 8.1700
  • 52 Week Range
    Low 4.2500
    High 10.9800
  • Volume
    283,815
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.85
TimeVolumePNT
09:32 ET68517.72
09:34 ET4007.89
09:36 ET9197.82
09:38 ET1007.83
09:39 ET19007.87
09:41 ET34087.92
09:43 ET14878.02
09:45 ET33528.075
09:48 ET3008.1
09:50 ET4008.09
09:52 ET79678.135
09:54 ET18198.07
09:56 ET1008.05
09:57 ET17508.05
09:59 ET10008.01
10:01 ET4007.91
10:03 ET28097.91
10:06 ET27977.89
10:08 ET5007.86
10:10 ET1007.875
10:12 ET1007.88
10:14 ET24407.93
10:15 ET13007.96
10:17 ET3007.97
10:19 ET2047.97
10:21 ET4007.98
10:24 ET4007.98
10:26 ET1008.02
10:28 ET13007.98
10:30 ET195757.955
10:32 ET2007.99
10:35 ET2628.01
10:37 ET52458.05
10:39 ET36508.105
10:42 ET27128.01
10:46 ET11008.0001
10:48 ET3008.015
10:50 ET14628.02
10:51 ET58107.98
10:53 ET14688.005
10:55 ET3007.98
10:57 ET1007.99
11:00 ET4007.995
11:02 ET6008.002
11:04 ET2008
11:06 ET4628.01
11:08 ET14048.04
11:09 ET26758.045
11:11 ET15008.045
11:13 ET608898.045
11:15 ET82238.045
11:18 ET45798.03
11:20 ET4008.035
11:22 ET2628.035
11:24 ET3008.035
11:26 ET9008.01
11:27 ET1658.02
11:29 ET2008.02
11:31 ET3008.025
12:07 ET10277.97
12:09 ET2007.91
12:12 ET3007.91
12:14 ET5007.905
12:16 ET1007.9012
12:18 ET8547.935
12:20 ET14007.92
12:21 ET40387.93
12:23 ET4007.94
12:25 ET12007.955
12:27 ET11007.96
12:30 ET2007.96
12:32 ET1007.98
12:34 ET5008
12:36 ET1007.995
12:38 ET6627.99
12:39 ET32457.995
12:41 ET1007.995
12:43 ET3008
12:45 ET4007.995
12:48 ET1007.995
12:50 ET3007.995
12:52 ET1007.995
12:54 ET2007.995
12:56 ET3007.995
12:57 ET14627.995
12:59 ET1007.995
01:01 ET1007.995
01:03 ET3007.995
01:06 ET3007.995
01:08 ET6837.995
01:10 ET18207.96
01:12 ET5007.965
01:14 ET1007.955
01:15 ET4007.94
01:17 ET41627.9112
01:19 ET4007.92
01:21 ET9007.95
01:24 ET5007.95
01:26 ET5317.93
01:28 ET11007.945
01:30 ET3007.945
01:32 ET2007.945
01:33 ET1007.935
01:35 ET20907.985
01:37 ET3627.985
01:39 ET9007.96
01:42 ET8007.94
01:46 ET2007.93
01:48 ET4007.9
01:50 ET2007.89
01:51 ET2007.885
01:53 ET21007.89
01:55 ET1007.885
01:57 ET2007.885
02:00 ET21007.86
02:06 ET3007.865
02:08 ET16007.875
02:09 ET6007.88
02:11 ET6007.91
02:13 ET7257.925
02:15 ET28697.905
02:18 ET1007.9
02:20 ET1007.895
02:22 ET11007.885
02:24 ET7327.86
02:26 ET2007.86
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPNT
POINT Biopharma Global Inc
868.6M
-9.8x
---
United StatesGERN
Geron Corp
853.9M
-7.0x
---
United StatesKURA
Kura Oncology Inc
839.5M
-6.8x
---
United StatesACRS
Aclaris Therapeutics Inc
924.1M
-11.6x
---
United StatesIGMS
IGM Biosciences Inc
800.2M
-4.1x
---
United StatesRCKT
Rocket Pharmaceuticals Inc
828.9M
-5.3x
---
As of 2022-09-30

Company Information

POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company, through its subsidiaries is focused on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's clinical-stage product candidates include PNT2003 and PNT2002 for the treatment of prostate cancer and neuroendocrine tumors. Its preclinical stage product candidates include Lu-PNT2004 and Lu-PNT2001. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2004 is a family of fibroblast activation protein-alpha (FAP-alpha), which targeted radioligands. PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors.

Contact Information

Headquarters
4850 West 78Th Street, 18Th FloorINDIANAPOLIS, IN, United States 46268
Phone
317-543-9957
Fax
302-655-5049

Executives

Executive Chairman of the Board
Allan Silber
Chief Executive Officer, Director
Joe Mccann
Chief Financial Officer
Bill Demers
Chief Operating Officer
Justyna Kelly
Executive Vice President - Clinical Development
Jessica Jensen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$868.6M
Revenue (TTM)
$0.00
Shares Outstanding
104.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.80
Book Value
$2.83
P/E Ratio
-9.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.